Marta Suárez-Pinilla1, Ángeles Fernández-Rodríguez2, Lorena Benavente-Fernández3, Sergio Calleja-Puerta3. 1. Department of Neurology, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain. Electronic address: mspin116125@hotmail.com. 2. Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain. 3. Department of Neurology, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.
Abstract
BACKGROUND: Intracerebral hemorrhage (ICH) is the most feared complication associated with vitamin K antagonists (VKAs). We performed a retrospective study on the clinicoradiologic characteristics that influence its outcome. METHODS: We reviewed the clinical histories and neuroimaging studies of all patients attended at the Hospital Universitario Central de Asturias in 2010-2011 who had an ICH while being on VKA and analyzed the differential characteristics between patients with acceptable versus poor outcomes attending to 3 end points: death, poor outcome (modified Rankin Scale [mRS] score ≥ 4) at discharge, and poor outcome 3 months later. Additionally, CHA2DS2-VASc and HAS-BLED scores (validated tools for prediction of the risk of stroke and major hemorrhage, respectively, in patients with atrial fibrillation) were calculated to assess a priori risk-benefit balance for anticoagulant therapy. RESULTS: Eighty patients entered the sample (median age of 79 years). A priori annual risk of major bleeding surpassed ischemic stroke risk-without anticoagulation-only in 4. Fifty percent of the patients had an initial Glasgow Coma Scale (GCS) score lower than 13; in 51.3%, initial international normalized ratio was above their therapeutic range. Median hematoma size was 24.75 cc(3); relevant growth (≥33%) occurred in 29.4% of patients with a second computed tomography scan. On multivariable analysis, overall in-hospital mortality (47.5%) was related to prior antiplatelet therapy (P = .008), GCS (P = .001), and perilesional edema size (P = .036). Baseline mRS (P = .058) and National Institutes of Health Stroke Scale (NIHSS) scores (P = .008) were associated with poor outcome at discharge (77.5%). Initial NIHSS (P = .005) and glycemia (P = .038) predicted 3-month poor outcome (68.3%). VKA reversal was performed in almost all patients, which prevented assessment of its therapeutic value. CONCLUSIONS: VKA-associated ICH presents in a particularly vulnerable population and has a poor prognosis that may be reliably predicted by several clinicoradiologic features.
BACKGROUND:Intracerebral hemorrhage (ICH) is the most feared complication associated with vitamin K antagonists (VKAs). We performed a retrospective study on the clinicoradiologic characteristics that influence its outcome. METHODS: We reviewed the clinical histories and neuroimaging studies of all patients attended at the Hospital Universitario Central de Asturias in 2010-2011 who had an ICH while being on VKA and analyzed the differential characteristics between patients with acceptable versus poor outcomes attending to 3 end points: death, poor outcome (modified Rankin Scale [mRS] score ≥ 4) at discharge, and poor outcome 3 months later. Additionally, CHA2DS2-VASc and HAS-BLED scores (validated tools for prediction of the risk of stroke and major hemorrhage, respectively, in patients with atrial fibrillation) were calculated to assess a priori risk-benefit balance for anticoagulant therapy. RESULTS: Eighty patients entered the sample (median age of 79 years). A priori annual risk of major bleeding surpassed ischemic stroke risk-without anticoagulation-only in 4. Fifty percent of the patients had an initial Glasgow Coma Scale (GCS) score lower than 13; in 51.3%, initial international normalized ratio was above their therapeutic range. Median hematoma size was 24.75 cc(3); relevant growth (≥33%) occurred in 29.4% of patients with a second computed tomography scan. On multivariable analysis, overall in-hospital mortality (47.5%) was related to prior antiplatelet therapy (P = .008), GCS (P = .001), and perilesional edema size (P = .036). Baseline mRS (P = .058) and National Institutes of Health Stroke Scale (NIHSS) scores (P = .008) were associated with poor outcome at discharge (77.5%). Initial NIHSS (P = .005) and glycemia (P = .038) predicted 3-month poor outcome (68.3%). VKA reversal was performed in almost all patients, which prevented assessment of its therapeutic value. CONCLUSIONS: VKA-associated ICH presents in a particularly vulnerable population and has a poor prognosis that may be reliably predicted by several clinicoradiologic features.
Authors: Ingrid Pabinger; Wilfried Lang; Franz Xaver Roithinger; Franz Weidinger; Sabine Eichinger-Hasenauer; Reinhold Glehr; Walter-Michael Halbmayer; Hans-Peter Haring; Bernd Jilma; Hans Christian Korninger; Sibylle Kozek-Langenecker; Paul Kyrle; Herbert Watzke; Ansgar Weltermann; Johann Willeit; Kurt Huber Journal: Wien Klin Wochenschr Date: 2014-10-03 Impact factor: 1.704
Authors: Carlos Estevez-Fraga; Maria Molina-Sanchez; Rodrigo Alvarez-Velasco; Pablo Agüero-Rabes; Leticia Crespo-Araico; Elena Viedma-Guiard; Antonio Cruz-Culebras; Consuelo Matute; Rocio Vera; Alicia De Felipe-Mimbrera; Jaime Masjuan Vallejo Journal: Stroke Res Treat Date: 2018-08-02
Authors: James Jm Loan; Angus B Gane; Laura Middleton; Brendan Sargent; Tom James Moullaali; Mark A Rodrigues; Laura Cunningham; Joanna Wardlaw; Rustam Al-Shahi Salman; Neshika Samarasekera Journal: Int J Stroke Date: 2020-11-25 Impact factor: 5.266